KR870000931B1 - 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법 - Google Patents

이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법 Download PDF

Info

Publication number
KR870000931B1
KR870000931B1 KR1019830002255A KR830002255A KR870000931B1 KR 870000931 B1 KR870000931 B1 KR 870000931B1 KR 1019830002255 A KR1019830002255 A KR 1019830002255A KR 830002255 A KR830002255 A KR 830002255A KR 870000931 B1 KR870000931 B1 KR 870000931B1
Authority
KR
South Korea
Prior art keywords
compound
pyrazolo
evaporated
vacuo
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830002255A
Other languages
English (en)
Korean (ko)
Other versions
KR840004756A (ko
Inventor
에이. 디월드 호래이스
Original Assignee
워너-램버트 컴페니
제리 에이. 바이스바크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 컴페니, 제리 에이. 바이스바크 filed Critical 워너-램버트 컴페니
Publication of KR840004756A publication Critical patent/KR840004756A/ko
Application granted granted Critical
Publication of KR870000931B1 publication Critical patent/KR870000931B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019830002255A 1982-05-24 1983-05-23 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법 Expired KR870000931B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US381,484 1982-05-24
US06/381,484 US4469868A (en) 1982-05-24 1982-05-24 Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
US381484 1982-05-24

Publications (2)

Publication Number Publication Date
KR840004756A KR840004756A (ko) 1984-10-24
KR870000931B1 true KR870000931B1 (ko) 1987-05-11

Family

ID=23505215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002255A Expired KR870000931B1 (ko) 1982-05-24 1983-05-23 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법

Country Status (22)

Country Link
US (1) US4469868A (enExample)
EP (1) EP0095289B1 (enExample)
JP (1) JPS58210087A (enExample)
KR (1) KR870000931B1 (enExample)
AR (1) AR240941A1 (enExample)
AT (1) ATE24510T1 (enExample)
AU (1) AU553708B2 (enExample)
CA (1) CA1210393A (enExample)
DE (1) DE3368635D1 (enExample)
DK (1) DK161968C (enExample)
ES (4) ES522617A0 (enExample)
FI (1) FI74012C (enExample)
GR (1) GR79262B (enExample)
HK (1) HK102989A (enExample)
HU (1) HU187913B (enExample)
IE (1) IE55111B1 (enExample)
IL (1) IL68360A (enExample)
NO (1) NO160444C (enExample)
NZ (1) NZ204321A (enExample)
PH (1) PH18454A (enExample)
PT (1) PT76745B (enExample)
ZA (1) ZA832637B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000192A1 (en) * 1986-06-26 1988-01-14 Warner-Lambert Company 5-SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDIN-7-ONES
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
CN101248050B (zh) 2005-06-06 2013-07-17 武田药品工业株式会社 有机化合物
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CA2740388A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012143144A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
TWI686394B (zh) 2014-08-07 2020-03-01 美商內胞醫療公司 有機化合物
WO2016044667A1 (en) 2014-09-17 2016-03-24 Intra-Cellular Therapies, Inc. Compounds and methods
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
JP7612672B2 (ja) 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422807A (de) * 1963-08-16 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung von Imidazo- und Pyrimidochinazolinen
US3313815A (en) * 1964-05-04 1967-04-11 Sterling Drug Inc 8-chloropyrazolo-[1, 5-c]quinazoline derivatives and methods of preparing same
US3309369A (en) * 1966-04-11 1967-03-14 Wander Ag Dr A Imidazo- and pyrimido-quinazolines
US3594379A (en) * 1968-09-16 1971-07-20 Sandoz Ag 2,3-dihydroimidazo(1,2-c)quinazolines
DE2058501A1 (de) * 1970-11-27 1972-05-31 Bayer Ag Verfahren zur Herstellung von neuen N-verbrueckten bicyclischen Heteroaromaten
GB1347493A (en) * 1971-02-11 1974-02-27 Aspro Nicholas Ltd Benzazine derivatives
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
JPS516993A (en) * 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
JPS5398997A (en) * 1977-02-09 1978-08-29 Sumitomo Chem Co Ltd Fused pyridine derivertives and process for their preparation
US4250181A (en) * 1977-10-31 1981-02-10 The Upjohn Company Methods of treating psychosis
US4206123A (en) * 1977-10-31 1980-06-03 Mccall John M Isothiochroman
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
US4192803A (en) * 1978-09-15 1980-03-11 American Cyanamid Company 5H-Pyrrolo[2,1-c][1,4]benzodiazepine derivatives
GR69858B (enExample) * 1978-11-01 1982-07-19 Wellcome Found
CH643263A5 (de) * 1979-05-11 1984-05-30 Sandoz Ag Benzodiazepine, ihre herstellung und verwendung.
HU178523B (en) * 1979-05-18 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing new pyrazolo-quinazoline derivatives
US4230707A (en) * 1979-08-27 1980-10-28 Warner-Lambert Company Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their production
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4409230A (en) * 1982-04-09 1983-10-11 Hoechst-Roussel Pharmaceuticals Inc. Pharmaceutical compositions and methods employing 8-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro-[4.]decan-4-one and derivatives thereof
US4415581A (en) * 1982-04-09 1983-11-15 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines to treat psychoses
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
US4390544A (en) * 1982-04-09 1983-06-28 Hoechst-Roussel Pharmaceuticals Inc. {1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-oxo-1-benzimidazolinyl}p
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
HU187913B (en) 1986-03-28
DE3368635D1 (en) 1987-02-05
AU1342783A (en) 1983-12-01
NO831792L (no) 1983-11-25
AR240941A1 (es) 1991-03-27
KR840004756A (ko) 1984-10-24
US4469868A (en) 1984-09-04
ES8506315A1 (es) 1985-07-01
GR79262B (enExample) 1984-10-22
PT76745A (en) 1983-06-01
ATE24510T1 (de) 1987-01-15
NZ204321A (en) 1986-06-11
NO160444B (no) 1989-01-09
IL68360A0 (en) 1986-10-31
EP0095289A2 (en) 1983-11-30
AR240941A2 (es) 1991-03-27
ES529371A0 (es) 1985-07-01
DK161968C (da) 1992-02-03
FI74012B (fi) 1987-08-31
ES529372A0 (es) 1985-06-16
ES8407051A1 (es) 1984-09-01
NO160444C (no) 1989-04-19
DK161968B (da) 1991-09-02
ES8506004A1 (es) 1985-06-16
AU553708B2 (en) 1986-07-24
ES522617A0 (es) 1984-09-01
ZA832637B (en) 1984-01-25
FI831742A0 (fi) 1983-05-18
IE55111B1 (en) 1990-06-06
IL68360A (en) 1986-10-31
JPH0320395B2 (enExample) 1991-03-19
FI74012C (fi) 1987-12-10
FI831742L (fi) 1983-11-25
DK227183A (da) 1983-11-25
CA1210393A (en) 1986-08-26
EP0095289A3 (en) 1984-09-05
JPS58210087A (ja) 1983-12-07
ES529373A0 (es) 1985-06-16
PT76745B (en) 1986-04-21
DK227183D0 (da) 1983-05-20
EP0095289B1 (en) 1986-12-30
PH18454A (en) 1985-07-18
ES8506019A1 (es) 1985-06-16
HK102989A (en) 1990-01-05
IE830822L (en) 1983-11-24

Similar Documents

Publication Publication Date Title
KR870000931B1 (ko) 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법
US4435403A (en) Pharmacologically active 3-substituted beta-carbolines
DE60219672T2 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
JP5123949B2 (ja) 非ヌクレオシド逆転写酵素阻害剤
KR940010034B1 (ko) 헤테로사이클릭 퀴녹살린 화합물의 제조방법
KR100225720B1 (ko) 부신피질자극호르몬-방출 인자 길항제로서의 피라졸로피리미딘을 포함하는 약학 조성물
JPH0739387B2 (ja) 新規１−ベンジル−アミノアルキル−ピロリジノン化合物及びその製造方法
AU2001244398B2 (en) Pyrazolo-triazine derivatives as ligands for gaba receptors
JPH01190684A (ja) イミダゾキノキサリン化合物、その製造方法および用途
EP0336466B1 (en) Antiviral tetrahydroimidazo (1,4) benzodiazepin-2-ones
JPH07116195B2 (ja) ベンゾジアゼピン誘導体、その製法、並びにそれを使用する中枢神経病治療剤
KR940010035B1 (ko) 헤테로사이클릭 퀴나졸린 화합물의 제조방법
CZ2000320A3 (cs) Deriváty 4-oxo-3,5­dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostředek, který je obsahuje
JP2002512235A (ja) 新規ジフェニル置換５員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用
JP2002501071A (ja) Ｇａｂａ受容体のリガンドとしてのトリアゾロ−ピリダジン誘導体
US6949549B2 (en) Imidazolophthalazine derivatives as ligands for GABAA receptors
FI71560B (fi) Foerfarande foer framstaellning av nya analgetiska antiflogistiska och antipyretiska 1,4,9,10-tetrahydropyrazolo-/4,3-e/pyrido/3,2-b//1,4/diazepin-10-oner
CZ94297A3 (en) Novel heterocyclic substituted imidazoloquinoxalinones, process of their preparation and use
CZ180793A3 (en) Novel 3-oxadiazolyl-1,6-naphthyridine derivatives
KR20020053091A (ko) 인식 증강용 피라졸로[1,5-ｄ][1,2,4]트리아진
JPH0344392A (ja) ４Ｈ‐インドロ〔１，２‐ｄ〕〔１，２，４〕トリアゾロ〔４，３‐ａ〕〔１，４〕ベンゾジアゼピンおよびその製造法
JPS61227584A (ja) ポリアザ複素環誘導体
PL174418B1 (pl) Nowe związki, pochodne pirydo [1,2,3-de] chinoksaliny i sposób wytwarzania nowych związków, pochodnych pirydo [1,2,3-de] chinoksaliny
KR800000088B1 (ko) 치환된 6-아릴-4H-s-트리아졸로-[3, 4c]-티에노-[2, 3e]-1, 4-디아제핀의 제조방법
JPH0239512B2 (enExample)

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 19910419

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19920512

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19920512

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000